



DEC 04 1998

GROUP 1800

Sheet 2 of 3

Form PTO-1449 (Substituted)
(REV. 8-83)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
50634-B/JPW/JML/YLSERIAL NO.
09/053,872**INFORMATION DISCLOSURE CITATION**
(Use several sheets if necessary)APPLICANTS
Eric Rose, et al.FILING DATE
April 1, 1998GROUP
1643-1653**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|----|--|
| JR | Benedict, C. R., et al., Endothelial-Dependent Procoagulant and Anticoagulant Mechanisms, <u>Texas Heart Institute Journal</u> , 21: 86-90, 1994; |
| JR | Berntorp, E., Biochemical and in vivo properties of high purity factor IX concentrates, <u>Thrombosis and Haemostasis</u> , 70(5):768-773, 11/1993; |
| JR | Freedman, S.J. et al., Structure of the metal-free γ -carboxyglutamic acid-rich membrane binding region of factor IX by two-dimensional NMR spectroscopy, <u>J. Biol. Chem.</u> , 270(14):7980-7987, 04/1995; |
| JR | Furie, B.C. and Furie, B. (1995) Biosynthesis of factor IX: implications for gene therapy, <u>Thrombosis and Haemostasis</u> , 74(1):274-277; |
| JR | Iberti, T.J. et al., Abnormal coagulation profile in brain tumor patients during surgery, <u>Neurosurgery</u> , 34(3):389-395, 03/1994; |
| JR | Kirchhofer, et al. (1995) Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model, <u>Arterioscler. Thromb. Vasc. Biol.</u> , 15:1098-1106; |
| JR | Kuwabara, K. et al., Calreticulin, an antithrombotic agent which binds to vitamin K-dependent coagulation factors, stimulates endothelial nitric oxide production, and limits thrombosis in canine coronary arteries, <u>J. Biol. Chem.</u> , 270(14):8179-8187, 04/1995; |
| JR | Miyata, T. et al., Factor IX Bm Kiryu: a Val-313-to-Asp substitution in the catalytic domain results in loss of function due to a conformational change of the surface loop: evidence obtained by chimeric modeling, <u>Brit. J. Of Haematol.</u> , 88(1):156-165, 09/1994; |

EXAMINER

Jeffrey E. Russel

DATE CONSIDERED

November 3, 2001

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED
DEC 04 1998
GROUP 1800

Sheet 2 of 3

Form PTO-1449 (Substituted)
(REV. 8-83)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
50634-B/JPW/JML/YL

SERIAL NO.
09/053,872

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANTS
Eric Rose, et al.

FILING DATE
April 1, 1998

GROUP
~~1643~~ 1653

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|----|--|
| JR | Benedict, C. R., et al., Endothelial-Dependent Procoagulant and Anticoagulant Mechanisms, <u>Texas Heart Institute Journal</u> , 21: 86-90, 1994; |
| JR | Berntorp, E., Biochemical and in vivo properties of high purity factor IX concentrates, <u>Thrombosis and Haemostasis</u> , 70(5):768-773, 11/1993; |
| JR | Freedman, S.J. et al., Structure of the metal-free γ -carboxyglutamic acid-rich membrane binding region of factor IX by two-dimensional NMR spectroscopy, <u>J. Biol. Chem.</u> , 270(14):7980-7987, 04/1995; |
| JR | Furie, B.C. and Furie, B. (1995) Biosynthesis of factor IX: implications for gene therapy, <u>Thrombosis and Haemostasis</u> , 74(1):274-277; |
| JR | Iberti, T.J. et al., Abnormal coagulation profile in brain tumor patients during surgery, <u>Neurosurgery</u> , 34(3):389-395, 03/1994; |
| JR | Kirchhofer, et al. (1995) Active site-blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model, <u>Arterioscler. Thromb. Vasc. Biol.</u> , 15:1098-1106; |
| JR | Kuwabara, K. et al., Calreticulin, an antithrombotic agent which binds to vitamin K-dependent coagulation factors, stimulates endothelial nitric oxide production, and limits thrombosis in canine coronary arteries, <u>J. Biol. Chem.</u> , 270(14):8179-8187, 04/1995; |
| JR | Miyata, T. et al., Factor IX Bm Kiryu: a Val-313-to-Asp substitution in the catalytic domain results in loss of function due to a conformational change of the surface loop: evidence obtained by chimeric modeling, <u>Brit. J. Of Haematol.</u> , 88(1):156-165, 09/1994; |

EXAMINER

Jeffrey E. Russell

DATE CONSIDERED

November 3, 2001

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

